Bluebird Bio’s Gene Therapy for Blood Disease Wins European Approval

Bluebird Bio has won regulatory approval for its first gene therapy, a treatment for the rare blood disease beta thalassemia.

Cambridge, MA-based Bluebird said Monday that the European Commission’s regulatory nod for its therapy, Zynteglo, is a conditional approval, meaning the decision was made with less data than typically required for new drugs.